Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | An insight into ongoing trials in CMML

Eric Padron • 26 Aug 2022
Texas MPN Workshop 2022
Chronic Myelomonocytic Leukemia Leukemia Myeloproliferative Neoplasms Rare Diseases Ruxolitinib

Eric Padron, MD, H. Lee Moffitt Cancer Center, Tampa, FL, briefly discusses some ongoing trials evaluating therapeutic approaches in chronic myelomonocytic leukemia (CMML). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research Funding: Kura, Incyte, BMS
Honoraria: Blueprint, Novartis, Stem line, Taiho, Pharmaessentia

More from Eric Padron

CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for hematologists
Eric Padron et al. • 25 Mar 2024
1:31
The potential of bringing CAR-T therapy to MDS and challenges to overcome
Eric Padron • 9 Dec 2022
0:53
Challenges with bringing novel immune therapies to MDS
Eric Padron • 9 Dec 2022
1:32
Phase II efficacy and safety results of ruxolitinib for patients with symptomatic CMML
Eric Padron • 9 Dec 2022

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
0:46
The urgency of diagnosing and treating patients with Castleman disease
Karthik Ramasamy • 28 Apr 2024
1:35
Addressing the increased risk of cardiovascular disease in patients with MPNs
Arjun Ghosh • 25 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals